|
⚲
|
| Keyboard |
| Frazier Life Sciences Management LP
✚
|
|
|---|---|
| CRD # | 317522 |
| SEC # | 801-122904 |
| CIK # | 0001892134 |
| AUM | 6,966.9 M (2026-03-31) |
| Employees | 64 (73% Investors, 0% Brokers) |
| Fees | |
| Minimum | |
| Phone | 650-325-5156 |
| Address | 1001 Page Mill Road Palo Alto, CA 94304 |
| Source | [IAPD] [EDGAR] [Website] [LinkedIn] |
| Total AUM ($B) |
|---|
| CIK | Period |
|---|---|
| 0001892134 |
| Sector | Form 13F Holdings | Value ($B) | |
|---|---|---|---|
| Mirum Pharmaceuticals Inc | 0.7 | ||
| Newamsterdam Pharma Co NV | 0.5 | ||
| Erasca Inc | 0.4 | ||
| Bridgebio Pharma Inc | 0.3 | ||
| Arcutis Biotherapeutics Inc | 0.2 | ||
| MBX Biosciences Inc | 0.2 | ||
| Phathom Pharmaceuticals Inc | 0.1 | ||
| MAZE Therapeutics Inc | 0.1 | ||
| Krystal Biotech Inc | 0.1 | ||
| Trevi Therapeutics Inc | 0.1 | ||
| Marika Inc | 0.1 | ||
| FS Development Corp | 0.1 | ||
| Cytokinetics Inc | 0.1 | ||
| Revolution Medicines Inc | 0.1 | ||
| Dyne Therapeutics Inc | 0.1 | ||
| Adventrx Pharmaceuticals Inc | 0.1 | ||
| Tarsus Pharmaceuticals Inc | 0.1 | ||
| Vor Biopharma Inc | 0.0 | ||
| Agios Pharmaceuticals Inc | 0.0 | ||
| Biocryst Pharmaceuticals Inc | 0.0 | ||
| Zai Lab Ltd | 0.0 | ||
| AURA Biosciences Inc | 0.0 | ||
| Acadia Pharmaceuticals Inc | 0.0 | ||
| Ascendis Pharma A/S | 0.0 | ||
| Lexeo Therapeutics Inc | 0.0 | ||
| Alkermes PLC | 0.0 | ||
| Aclaris Therapeutics Inc | 0.0 | ||
| Monte Rosa Therapeutics Inc | 0.0 | ||
| Immunocore Holdings PLC | 0.0 | ||
| Prev | Page 1 | Next | |||
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| VC | Frazier Life Sciences XII LP | [2025-03-31] | 1,350.6 M | |
| Filed 2025-03-17 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Not Applicable | ||||
| HF | Frazier Life Sciences Public Overage Fund LP | [2023-03-31] | 243.1 M | 362.2 M |
| Offered $243,146,976 · Filed 2022-04-14 (D) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Minimum $3,968 · Duration One year or less · Revenue Decline to Disclose | ||||
| HF | Frazier Life Sciences Public Fund LP | [2022-03-31] | 2,868.0 M | |
| Offered $617,050,000 · Filed 2019-12-17 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining $617,050,000 · Duration One year or less · Revenue Not Applicable | ||||
| VC | Frazier Life Sciences Xi LP | [2022-03-31] | 960.0 M | 1,107.8 M |
| Offered $960,000,000 · Filed 2022-03-18 (D) · Exemption 506(b), 3(c), 3(c)(7) · Duration One year or less · Revenue Not Applicable | ||||
| PE | Frazier Life Sciences X LP | [2020-03-30] | 781.2 M | |
| Offered $617,050,000 · Filed 2019-12-17 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining $617,050,000 · Duration One year or less · Revenue Not Applicable | ||||
| VC | Frazier Life Sciences IX LP | [2018-03-30] | 418.9 M | 596.5 M |
| Offered $418,925,000 · Filed 2017-11-01 (D) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Duration One year or less · Revenue Not Applicable | ||||
| VC | Frazier Life Sciences VIII LP | [2016-03-29] | 262.0 M | 260.2 M |
| Offered $262,000,000 · Filed 2015-10-29 (D) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Minimum $68,750 · Duration One year or less · Revenue Not Applicable | ||||
| AUM Breakdown | Accounts | AUM ($B) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 8 | 7.0 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 8 | 7.0 |
| By Discretionary | ||
| Discretionary | 8 | 7.0 |
| Non-Discretionary | 0 | 0.0 |
| Total | 8 | 7.0 |
| By Non-United States Persons | ||
| Non-United States Persons | 0.0 | |
| United States Persons | 7.0 | |
| Total | 8 | 7.0 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Patrick Heron | Executive Officer | 59 | 3 | |
| James Topper | Executive Officer | 58 | 3 | |
| Nader Naini | Promoter | 43 | 3 | |
| Nathan Every | Promoter | 41 | 3 | |
| Steve Bailey | Executive Officer | 23 | 3 | |
| Alan Frazier | Promoter | 16 | 3 | |
| Daniel Estes | Executive Officer, Promoter | 10 | 2 | |
| Frazier Management LLC | Promoter | 6 | 2 | |
| Fhmlsp Overage LP | Promoter | 2 | 2 | |
| Fhmlsp Overage LLC | Promoter | 2 | 2 | |
| View All | ||||
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001892134] |
| Firm Profile (Form ADV) | |
|---|---|
| Serves | Institutional |
| Fund Types | Hedge Fund, Private Equity |
| LEI | 254900K7JVMHHKW0QH33 |
| Comparable Firms | State | AUM |
|---|---|---|
|
Arbour Lane Capital Management LP
✚
|
CT | 7,297.3 M |
|
Peak Rock Capital LLC
✚
|
TX | 7,275.0 M |
|
Caspian Capital LP
✚
|
NY | 7,026.2 M |
|
Tilden Park Capital Management LP
✚
|
NY | 6,836.6 M |
|
First Sentier Investors Australia RE Ltd
✚
|
6,826.5 M | |
|
Atairos Management LP
✚
|
PA | 6,786.2 M |
|
Lead Edge Capital Management LLC
✚
|
NY | 6,766.5 M |
|
Discovery Capital Management LLC
✚
|
CT | 6,748.6 M |
|
BC Partners Advisors LP
✚
|
NY | 6,688.9 M |
|
NXT Capital Investment Advisers LLC
✚
|
IL | 6,647.9 M |